Literature DB >> 21094209

Cannabinoids attenuate cancer pain and proliferation in a mouse model.

Negin Saghafi1, David K Lam, Brian L Schmidt.   

Abstract

We investigated the effects of cannabinoid receptor agonists on (1) oral cancer cell viability in vitro and (2) oral cancer pain and tumor growth in a mouse cancer model. We utilized immunohistochemistry and Western blot to show that human oral cancer cells express CBr1 and CBr2. When treated with WIN55,212-2 (non-selective), ACEA (CBr1-selective) or AM1241 (CBr2-selective) agonists in vitro, oral cancer cell proliferation was significantly attenuated in a dose-dependent manner. In vivo, systemic administration (0.013M) of WIN55,212-2, ACEA, or AM1241 significantly attenuated cancer-induced mechanical allodynia. Tumor growth was also significantly attenuated with systemic AM1241 administration. Our findings suggest a direct role for cannabinoid mechanisms in oral cancer pain and proliferation. The systemic administration of cannabinoid receptor agonists may have important therapeutic implications wherein cannabinoid receptor agonists may reduce morbidity and mortality of oral cancer. Copyright Â
© 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21094209      PMCID: PMC3099480          DOI: 10.1016/j.neulet.2010.11.039

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  32 in total

1.  Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation.

Authors:  I Galve-Roperh; C Sánchez; M L Cortés; T Gómez del Pulgar; M Izquierdo; M Guzmán
Journal:  Nat Med       Date:  2000-03       Impact factor: 53.440

2.  Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.

Authors:  C Sánchez; M L de Ceballos; T Gomez del Pulgar; D Rueda; C Corbacho; G Velasco; I Galve-Roperh; J W Huffman; S Ramón y Cajal; M Guzmán
Journal:  Cancer Res       Date:  2001-08-01       Impact factor: 12.701

Review 3.  Head and neck cancer.

Authors:  E E Vokes; R R Weichselbaum; S M Lippman; W K Hong
Journal:  N Engl J Med       Date:  1993-01-21       Impact factor: 91.245

Review 4.  Cannabinoids: potential anticancer agents.

Authors:  Manuel Guzmán
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

5.  Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease.

Authors:  Robert J McKallip; Catherine Lombard; Michael Fisher; Billy R Martin; Seongho Ryu; Steven Grant; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

6.  A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain.

Authors:  Lois J Kehl; Darryl T Hamamoto; Paul W Wacnik; Devin L Croft; Blake D Norsted; George L Wilcox; Donald A Simone
Journal:  Pain       Date:  2003-05       Impact factor: 6.961

7.  Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors.

Authors:  M Llanos Casanova; Cristina Blázquez; Jesús Martínez-Palacio; Concepción Villanueva; M Jesús Fernández-Aceñero; John W Huffman; José L Jorcano; Manuel Guzmán
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

8.  Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor.

Authors:  Stefan Hart; Oliver M Fischer; Axel Ullrich
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

9.  Methanandamide increases COX-2 expression and tumor growth in murine lung cancer.

Authors:  Brian Gardner; Li X Zhu; Sherven Sharma; Donald P Tashkin; Steven M Dubinett
Journal:  FASEB J       Date:  2003-09-04       Impact factor: 5.191

10.  Peripheral endothelin B receptor agonist-induced antinociception involves endogenous opioids in mice.

Authors:  Phuong N Quang; Brian L Schmidt
Journal:  Pain       Date:  2010-03-04       Impact factor: 7.926

View more
  7 in total

Review 1.  Biologic mechanisms of oral cancer pain and implications for clinical therapy.

Authors:  C T Viet; B L Schmidt
Journal:  J Dent Res       Date:  2011-10-04       Impact factor: 6.116

2.  Vanilloids induce oral cancer apoptosis independent of TRPV1.

Authors:  Cara B Gonzales; Nameer B Kirma; Jorge J De La Chapa; Richard Chen; Michael A Henry; Songjiang Luo; Kenneth M Hargreaves
Journal:  Oral Oncol       Date:  2014-01-14       Impact factor: 5.337

3.  The non-selective cannabinoid receptor agonist WIN 55,212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer pain.

Authors:  M L Uhelski; D M Cain; C Harding-Rose; D A Simone
Journal:  Neuroscience       Date:  2013-05-11       Impact factor: 3.590

4.  Novelty-induced emotional arousal modulates cannabinoid effects on recognition memory and adrenocortical activity.

Authors:  Patrizia Campolongo; Maria Morena; Sergio Scaccianoce; Viviana Trezza; Flavia Chiarotti; Gustav Schelling; Vincenzo Cuomo; Benno Roozendaal
Journal:  Neuropsychopharmacology       Date:  2013-01-22       Impact factor: 7.853

5.  Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma.

Authors:  Cara B Gonzales; Jorge J De La Chapa; Pothana Saikumar; Prajjal K Singha; Nicholas F Dybdal-Hargreaves; Jeffery Chavez; Aaron M Horning; Jamie Parra; Nameer B Kirma
Journal:  Oral Oncol       Date:  2016-08       Impact factor: 5.337

Review 6.  The neurobiology of cancer pain.

Authors:  Brian L Schmidt
Journal:  Neuroscientist       Date:  2014-03-24       Impact factor: 7.519

Review 7.  Pain in laboratory animals: the ethical and regulatory imperatives.

Authors:  Larry Carbone
Journal:  PLoS One       Date:  2011-09-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.